245 related articles for article (PubMed ID: 30210633)
1. Clinical Value of Combining
Sookha RR; Zhi W; Shen Y; Lazare C; Wang L; Meng Y; Cao C; Hu J; Wu P
J Cancer; 2018; 9(17):3101-3108. PubMed ID: 30210633
[No Abstract] [Full Text] [Related]
2. Clinical Usefulness of (18)F-FDG PET/CT in the Detection of Early Recurrence in Treated Cervical Cancer Patients with Unexplained Elevation of Serum Tumor Markers.
Chong A; Ha JM; Jeong SY; Song HC; Min JJ; Bom HS; Choi HS
Chonnam Med J; 2013 Apr; 49(1):20-6. PubMed ID: 23678473
[TBL] [Abstract][Full Text] [Related]
3. Detection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[
Peng NJ; Hu C; Chiu YL; Yu CC; Li CJ; Sheu JJ; Chiang AJ
Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32878219
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of
Zhang XC; Zhang JH; Wang RF; Fan Y; Fu ZL; Yan P; Zhao GY; Bai YX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1071-1077. PubMed ID: 31848507
[TBL] [Abstract][Full Text] [Related]
5. Complementary Roles of Squamous Cell Carcinoma Antigen and (18)F-FDG PET/CT in Suspected Recurrence of Cervical Squamous Cell Cancer.
Hu YY; Fan W; Zhang X; Liang PY; Lin XP; Zhang YR; Li YH
J Cancer; 2015; 6(3):287-91. PubMed ID: 25663947
[TBL] [Abstract][Full Text] [Related]
6. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
[TBL] [Abstract][Full Text] [Related]
7. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
8. A study on the clinical value of
Qi C; He S; Cai L; Zhang L; Ding H; Chen Y
Oncol Lett; 2021 Nov; 22(5):746. PubMed ID: 34539850
[TBL] [Abstract][Full Text] [Related]
9. [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
Hu YY; Sun XR; Lin XP; Liang PY; Zhang X; Fan W
Ai Zheng; 2009 Sep; 28(9):994-9. PubMed ID: 19728921
[TBL] [Abstract][Full Text] [Related]
10. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
Kyoto Y; Momose M; Kondo C; Itabashi M; Kameoka S; Kusakabe K
Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
[TBL] [Abstract][Full Text] [Related]
11. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
12. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET-CT in Unknown-Source of Elevated Serum Carcinoembryonic Antigen (CEA) Level.
Fu L; Li W; Tian X
J Coll Physicians Surg Pak; 2018 Dec; 28(12):910-913. PubMed ID: 30501825
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recurrent disease in the re-staging of colorectal cancer by
Chiaravalloti A; Fiorentini A; Palombo E; Rinino D; Lacanfora A; Danieli R; Di Russo C; Di Biagio D; Squillaci E; Schillaci O
Oncol Lett; 2016 Nov; 12(5):4209-4213. PubMed ID: 27895793
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
[TBL] [Abstract][Full Text] [Related]
20. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
